Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Antisense Therapeutics Ltd

+ Add to Watchlist

AWY:GR

0.075 EUR 0.008 11.94%

As of 02:08:02 ET on 04/21/2015.

Snapshot for Antisense Therapeutics Ltd (AWY)

Open: 0.075 Day's Range: 0.075 - 0.075 Volume: 0
Previous Close: 0.067 52wk Range: 0.045 - 0.098 1-Yr Rtn: -15.73%

Stock Chart for AWY

No chart data available.
  • AWY:GR 0.075
  • 1M
  • 1Y
0.067
Interactive AWY Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AWY

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. DAX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M EUR) 12.11
Shares Outstanding (M) 161.49
30 Day Average Volume 0
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/25/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AWY

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)

Company Profile & Key Executives for AWY

Antisense Therapeutics Limited develops and markets drugs for treatment of diseases like psoriasis, multiple sclerosis, autoimmune, cancer, metabolic and cardiovascular. The drugs are based on small synthetic genetic molecules. The Company has collaboration with Isis Pharmaceuticals in the United States, which provides the Company access to drug development technology.

Mark P DiamondCEO/Managing DirectorPhillip HainsCFO/Secretary
More Company Profile & Key Executives for AWY

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil